Skip to content

Genomic Evolution of Metastasis in Gastric Cancer

Genomic Evolution of Metastasis in Gastric Cancer

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05061082
Enrollment
20
Registered
2021-09-29
Start date
2021-10-26
Completion date
2022-10-31
Last updated
2022-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer, Metastasis

Keywords

Gastric Cancer, Metastasis

Brief summary

The aim of this study is to track tumor evolution of regional and distant metastases in gastric cancer using the Next Generation Sequencing technologies.

Detailed description

Gastric cancer is the fourth most common cancer in Vietnam with high mortality rate. Metastasis is the leading cause of death in gastric cancer patients, with median overall survival of less than 1 year. Currently, there is no effective treatment because the molecular mechanism of metastasis remains unclear. The aim of this study is to use advanced NGS technologies to dissect the genomic changes (genetic, epigenetic and transcriptional changes) of the primary tumor and associated metastatic sites of the same patients. With that, the investigators can reconstruct the clonal evolution from primary tumor to metastasis, identify key pathways governing metastasis development that can be targeted for future therapeutic development.

Interventions

None listed

Sponsors

University Medical Center Ho Chi Minh City (UMC)
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Male or Female patients aged 18 years and older 2. Histologically proven primary gastric adenocarcinoma and clinical evidence of metastasis (N1-3M1) 3. Biopsies can be taken at multiple sites 4. No known other concomitant cancer diagnosis 5. Signed informed consent

Exclusion criteria

1. Gastric adnocarcinoma cannot be confirmed primary 2. Unable to undergo biopsy or surgery

Design outcomes

Primary

MeasureTime frameDescription
Genetic and epigenetic changes of the tumor3 months after surgeryUltra-deep NGS of the primary tumor and associated metastatic sites from the same patients to identify mechanism governing metastasis development

Countries

Vietnam

Contacts

Primary ContactLong Duy Vo, MD, PhD
long.vd@umc.edu.vn+84. 918133915

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026